New THC-CBD Pill for MS and Huntington’s Disease May Be First to Benefit from Biden’s New Marijuana Research Bill
December 22, 2022
In related news, President Biden signed the Marijuana Research and Expansion Act into law. This will speed up researchers’ bids for DEA schedule 1 registration authorization to undertake these trials. After seven hard years of waiting, the MMJ group of firms can finish their mission of performing clinical studies on Huntington’s Disease and Multiple Sclerosis. MMJ has received FDA Orphan Designation for its Huntington’s disease clinical trials.